

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
03 September 2020 (03.09.2020)



(10) International Publication Number  
**WO 2020/176397 A1**

(51) International Patent Classification:

*A61K 47/69* (2017.01)      *A61K 47/59* (2017.01)  
*A61K 39/00* (2006.01)      *A61P 35/00* (2006.01)  
*C12N 15/86* (2006.01)      *A61P 37/04* (2006.01)  
*C12N 5/0783* (2010.01)

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(21) International Application Number:

PCT/US2020/019461

(22) International Filing Date:

24 February 2020 (24.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/810,260      25 February 2019 (25.02.2019)      US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,  
4056 Basel (CH).

(72) Inventors; and

(71) Applicants (*for US only*): **KOSHY, Sandeep, Tharian**  
[CA/US]; Novartis Institutes for Biomedical Research, Inc.,  
250 Massachusetts Avenue, Cambridge, MA 02142 (US).  
**CANHAM, Stephen, M.** [US/US]; Novartis Institutes for  
Biomedical Research, Inc., 250 Massachusetts Avenue,  
Cambridge, MA 02142 (US).

(74) Agent: **COLLAZO, Diana, M.** et al.; Lando & Anastasi,  
LLP, 60 State Street, 23rd Floor, Boston, MA 02109 (US).

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(54) Title: MESOPOROUS SILICA PARTICLES COMPOSITIONS FOR VIRAL DELIVERY

(57) Abstract: The present invention relates generally to the use of compositions including mesoporous silica particles that may be surface modified, for the delivery of viral vectors. In some embodiments, the viral vectors are used to transduce T cells to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.

WO 2020/176397 A1